10/10/2016
Prostate Cancer Screening and You
Nobody wants to think about cancer, especially prostate cancer. Nobody wants to get screened, and especially, nobody wants to even think about getting a rectal exam to check for prostate cancer. We get that. Read More
Why Genes Matter
We're in the midst of a revolution in how prostate cancer is treated — and it's being led by new knowledge about the genes behind the disease. Read More
10/07/2016
Guys: Don’t Put it Off Like I Did. Get Checked!
While each patient’s battle with prostate cancer is an individual one, my experience is hardly unique. My story began 4 years ago, back in 2011, when my wife Susan literally begged me to see a doctor for a physical exam. At the time, I was dismissive—even incredulous at this suggestion—even though 2 of my close relatives, my. Read More
10/06/2016
African American? What You Need to Know About Prostate Cancer
In the United States, men of African descent are more likely to develop prostate cancer than any other race or ethnicity. Read More
Progress Report: Andrea Harzstark, MD
Investigator: Andrea Harzstark, MD – Assistant Professor, University of California, San Francisco Tobacco and Prostate Cancer Therapy: The Missing Link? Prostate cancer affects one in every six American men; ~25% of those men are smokers. Smoking causes many health risks, including a higher risk for lung cancer. Many of the. Read More
Progress Report: Thomas Guzzo, MD, MPH
Investigator: Thomas Guzzo, MD, MPH – Assistant Professor, University of Pennsylvania Reducing Morbidity from Surgery and Physician Counseling of Treatment Costs Dr. Guzzo has had a very prolific second year as a PCF Young Investigator as evidenced by his publication of ten scientific and clinical reports. His primary research aims. Read More
Progress Report: Steven Frank, MD
Investigator: Steven Frank, MD– Assistant Professor, University of Texas, M.D. Anderson Cancer Center C4 and MRI-based Prostate Brachytherapy Brachytherapy is a form of radiotherapy where a radiation source, called “seeds”, is precisely implanted into the prostate such that emitted radiation will abolish the tumor. Recent technological advances have increased the. Read More
Progress Report: Adam S. Feldman, MD, MPH
Investigator: Adam S. Feldman, MD, MPH–Assistant Professor of Surgery, Massachusetts General Hospital, Harvard School of Medicine Active Surveillance: Identifying When to Treat and When Not to Treat In 2010 nearly 218,000 men will be diagnosed with prostate cancer in the United States. However, ~50% of those men will have low. Read More
Progress Report: Eleni Efstathiou, MD, Ph.D
Investigator: Eleni Efstathiou, MD, PhD – Assistant Professor, University of Texas, M.D. Anderson Cancer Center Biomarker Driven Application of Therapy Androgens (male hormones such as testosterone) fuel prostate cancer growth and survival. Androgens are synthesized in the testis and adrenal glands. Therapeutic agents that block the production of androgens (androgen. Read More
Progress Report: Scott Dehm, Ph.D
Investigator: Scott Dehm, PhD – Assistant Professor, University of Minnesota Mechanisms of Androgen Receptor (AR) Activation in Prostate Cancer The standard first line treatment strategy for metastatic prostate cancer is androgen (male hormones) deprivation therapy, such as Lupron, which reduces the level of circulating testosterone (type of androgen), or such. Read More